Rhumbline Advisers Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Rhumbline Advisers increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 3.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 321,154 shares of the biotechnology company’s stock after buying an additional 12,022 shares during the quarter. Rhumbline Advisers owned about 0.15% of BioCryst Pharmaceuticals worth $2,409,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 5,449 shares in the last quarter. California State Teachers Retirement System raised its stake in BioCryst Pharmaceuticals by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 184,485 shares of the biotechnology company’s stock valued at $1,387,000 after acquiring an additional 7,232 shares in the last quarter. Mackenzie Financial Corp raised its stake in BioCryst Pharmaceuticals by 190.7% during the 4th quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock valued at $637,000 after acquiring an additional 55,535 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $33,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of BioCryst Pharmaceuticals by 3.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after acquiring an additional 11,581 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of research reports. Barclays lifted their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Needham & Company LLC upped their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $16.56.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $10.29 on Tuesday. The business’s 50-day moving average price is $9.45 and its two-hundred day moving average price is $8.42. BioCryst Pharmaceuticals, Inc. has a 1 year low of $5.92 and a 1 year high of $11.31. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -16.87 and a beta of 1.11.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.